ST SC Pharmaceuticals: Passed the drug GMP compliance inspectionZhitong·Aug 26, 2025 at 04:00 AM002693+10.01%
ST SC Pharmaceuticals released its half-year performance, with a net loss attributable to shareholders of 18.4666 million yuan, an increase of 8.97%Zhitong·Jul 30, 2025 at 03:44 AM002693+10.01%
ST SC Pharmaceuticals: Eptinezumab injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of AustraliaZhitong·May 19, 2025 at 04:57 AM002693+10.01%
ST SC Pharmaceuticals: Injectable Paclitaxel (Albumin-Bound) ANDA approved for market by the U.S. FDAZhitong·May 16, 2025 at 04:32 AM002693+10.01%
ST SC Pharmaceuticals: Injectable Bivalirudin has obtained market approval from the Therapeutic Goods Administration (TGA) of AustraliaZhitong·May 6, 2025 at 05:10 AM002693+10.01%
CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit downZhitong·Apr 27, 2025 at 08:30 PM002581+0.58%002693+10.01%
SC Pharmaceuticals hit the daily limit today, with one institutional special seat net selling 11.4106 million yuanZhitong·Apr 24, 2025 at 03:25 AM002693+10.01%
The three major A-share indices opened lower collectively, RoboTechnik opened up 9.38%36Kr·Apr 17, 2025 at 08:32 PM300757+3.59%002693+10.01%
SC Pharmaceuticals: May be subject to delisting risk warning after the disclosure of the 2024 annual reportZhitong·Apr 16, 2025 at 04:14 AM002693+10.01%
Synthetic biology concept stocks strengthen, SHENGDA BIO-PHARM hits the daily limit in the afternoonZhitong·Apr 10, 2025 at 01:27 AM603079+1.05%301206+0.34%
SC Pharmaceuticals: An investor briefing will be held on March 13 regarding the termination of the issuance of shares and cash payment for asset purchases, as well as the fundraising for supporting funds and related party transactionsZhitong·Mar 11, 2025 at 03:49 AM002693+10.01%
SC Pharmaceuticals fell over 6% and again warned of potential *ST statusZhitong·Feb 26, 2025 at 12:25 AM002693+10.01%
SC Pharmaceuticals expects to incur losses in 2024 and revenue to be below 300 million yuan, and may face delisting risk warnings after disclosing its annual reportZhitong·Jan 17, 2025 at 08:06 AM002693+10.01%
SC Pharmaceuticals: Expected net profit loss of 55 million to 80 million yuan in 2024Zhitong·Jan 17, 2025 at 06:56 AM002693+10.01%
